Targeting lung cancer using an infectivity enhanced CXCR4-CRAd

Zeng B. Zhu, Angel A. Rivera, Sharmila K. Makhija, Baogen Lu, Minghui Wang, Miiru Izumi, Robert J. Cerfolio, Mariam A. Stoff-Khalili, Fen Zhou, Koichi Takayama, Gene P. Siegal, David T. Curiel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Conventional treatments are not adequate for the majority of lung cancer patients. Conditionally replicating adenoviruses (CRAds) represent a promising new modality for the treatment of neoplastic diseases, including non-small cell lung cancer. Specifically, following cellular infection, the virus replicates selectively in the infected tumor cells and kills the cells by cytolysis. Next, the progeny virions infect a new population of surrounding target cells, replicate again and eradicate the infected tumor cells while leaving normal cells unaffected. However, to date, there have been two main limitations to successful clinical application of these CRAd agents; i.e. poor infectivity and poor tumor specificity. Here we report the construction of a CRAd agent, CRAd-CXCR4.RGD, in which the adenovirus E1 gene is driven by a tumor-specific CXCR4 promoter and the viral infectivity is enhanced by a capsid modification, RGD4C. This agent CRAd-CXCR4.RGD, as expected, improved both of the viral infectivity and tumor specificity as evaluated in an established lung tumor cell line and in primary tumor tissue from multiple patients. As an added benefit, the activity of the CXCR4 promoter was low in human liver as compared to three other promoters regularly used for targeting tumors. In addition, this agent has the potential of targeting multiple other tumor cell types. From these data, the CRAd-CXCR4.RGD appears to be a promising novel CRAd agent for lung cancer targeting with low host toxicity.

Original languageEnglish (US)
Pages (from-to)145-156
Number of pages12
JournalLung Cancer
Volume55
Issue number2
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Adenoviridae
Lung Neoplasms
Neoplasms
Health Services Needs and Demand
Capsid
Virus Diseases
Tumor Cell Line
Non-Small Cell Lung Carcinoma
Virion
Lung
Liver
Therapeutics
Genes

Keywords

  • Adenoviral vector
  • CXCR4 gene
  • Transcriptional targeting
  • Tumor-specific promoter

ASJC Scopus subject areas

  • Oncology

Cite this

Zhu, Z. B., Rivera, A. A., Makhija, S. K., Lu, B., Wang, M., Izumi, M., ... Curiel, D. T. (2007). Targeting lung cancer using an infectivity enhanced CXCR4-CRAd. Lung Cancer, 55(2), 145-156. https://doi.org/10.1016/j.lungcan.2006.10.012

Targeting lung cancer using an infectivity enhanced CXCR4-CRAd. / Zhu, Zeng B.; Rivera, Angel A.; Makhija, Sharmila K.; Lu, Baogen; Wang, Minghui; Izumi, Miiru; Cerfolio, Robert J.; Stoff-Khalili, Mariam A.; Zhou, Fen; Takayama, Koichi; Siegal, Gene P.; Curiel, David T.

In: Lung Cancer, Vol. 55, No. 2, 02.2007, p. 145-156.

Research output: Contribution to journalArticle

Zhu, ZB, Rivera, AA, Makhija, SK, Lu, B, Wang, M, Izumi, M, Cerfolio, RJ, Stoff-Khalili, MA, Zhou, F, Takayama, K, Siegal, GP & Curiel, DT 2007, 'Targeting lung cancer using an infectivity enhanced CXCR4-CRAd', Lung Cancer, vol. 55, no. 2, pp. 145-156. https://doi.org/10.1016/j.lungcan.2006.10.012
Zhu, Zeng B. ; Rivera, Angel A. ; Makhija, Sharmila K. ; Lu, Baogen ; Wang, Minghui ; Izumi, Miiru ; Cerfolio, Robert J. ; Stoff-Khalili, Mariam A. ; Zhou, Fen ; Takayama, Koichi ; Siegal, Gene P. ; Curiel, David T. / Targeting lung cancer using an infectivity enhanced CXCR4-CRAd. In: Lung Cancer. 2007 ; Vol. 55, No. 2. pp. 145-156.
@article{aaeab02391b94668b930455f54ea2836,
title = "Targeting lung cancer using an infectivity enhanced CXCR4-CRAd",
abstract = "Conventional treatments are not adequate for the majority of lung cancer patients. Conditionally replicating adenoviruses (CRAds) represent a promising new modality for the treatment of neoplastic diseases, including non-small cell lung cancer. Specifically, following cellular infection, the virus replicates selectively in the infected tumor cells and kills the cells by cytolysis. Next, the progeny virions infect a new population of surrounding target cells, replicate again and eradicate the infected tumor cells while leaving normal cells unaffected. However, to date, there have been two main limitations to successful clinical application of these CRAd agents; i.e. poor infectivity and poor tumor specificity. Here we report the construction of a CRAd agent, CRAd-CXCR4.RGD, in which the adenovirus E1 gene is driven by a tumor-specific CXCR4 promoter and the viral infectivity is enhanced by a capsid modification, RGD4C. This agent CRAd-CXCR4.RGD, as expected, improved both of the viral infectivity and tumor specificity as evaluated in an established lung tumor cell line and in primary tumor tissue from multiple patients. As an added benefit, the activity of the CXCR4 promoter was low in human liver as compared to three other promoters regularly used for targeting tumors. In addition, this agent has the potential of targeting multiple other tumor cell types. From these data, the CRAd-CXCR4.RGD appears to be a promising novel CRAd agent for lung cancer targeting with low host toxicity.",
keywords = "Adenoviral vector, CXCR4 gene, Transcriptional targeting, Tumor-specific promoter",
author = "Zhu, {Zeng B.} and Rivera, {Angel A.} and Makhija, {Sharmila K.} and Baogen Lu and Minghui Wang and Miiru Izumi and Cerfolio, {Robert J.} and Stoff-Khalili, {Mariam A.} and Fen Zhou and Koichi Takayama and Siegal, {Gene P.} and Curiel, {David T.}",
year = "2007",
month = "2",
doi = "10.1016/j.lungcan.2006.10.012",
language = "English (US)",
volume = "55",
pages = "145--156",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Targeting lung cancer using an infectivity enhanced CXCR4-CRAd

AU - Zhu, Zeng B.

AU - Rivera, Angel A.

AU - Makhija, Sharmila K.

AU - Lu, Baogen

AU - Wang, Minghui

AU - Izumi, Miiru

AU - Cerfolio, Robert J.

AU - Stoff-Khalili, Mariam A.

AU - Zhou, Fen

AU - Takayama, Koichi

AU - Siegal, Gene P.

AU - Curiel, David T.

PY - 2007/2

Y1 - 2007/2

N2 - Conventional treatments are not adequate for the majority of lung cancer patients. Conditionally replicating adenoviruses (CRAds) represent a promising new modality for the treatment of neoplastic diseases, including non-small cell lung cancer. Specifically, following cellular infection, the virus replicates selectively in the infected tumor cells and kills the cells by cytolysis. Next, the progeny virions infect a new population of surrounding target cells, replicate again and eradicate the infected tumor cells while leaving normal cells unaffected. However, to date, there have been two main limitations to successful clinical application of these CRAd agents; i.e. poor infectivity and poor tumor specificity. Here we report the construction of a CRAd agent, CRAd-CXCR4.RGD, in which the adenovirus E1 gene is driven by a tumor-specific CXCR4 promoter and the viral infectivity is enhanced by a capsid modification, RGD4C. This agent CRAd-CXCR4.RGD, as expected, improved both of the viral infectivity and tumor specificity as evaluated in an established lung tumor cell line and in primary tumor tissue from multiple patients. As an added benefit, the activity of the CXCR4 promoter was low in human liver as compared to three other promoters regularly used for targeting tumors. In addition, this agent has the potential of targeting multiple other tumor cell types. From these data, the CRAd-CXCR4.RGD appears to be a promising novel CRAd agent for lung cancer targeting with low host toxicity.

AB - Conventional treatments are not adequate for the majority of lung cancer patients. Conditionally replicating adenoviruses (CRAds) represent a promising new modality for the treatment of neoplastic diseases, including non-small cell lung cancer. Specifically, following cellular infection, the virus replicates selectively in the infected tumor cells and kills the cells by cytolysis. Next, the progeny virions infect a new population of surrounding target cells, replicate again and eradicate the infected tumor cells while leaving normal cells unaffected. However, to date, there have been two main limitations to successful clinical application of these CRAd agents; i.e. poor infectivity and poor tumor specificity. Here we report the construction of a CRAd agent, CRAd-CXCR4.RGD, in which the adenovirus E1 gene is driven by a tumor-specific CXCR4 promoter and the viral infectivity is enhanced by a capsid modification, RGD4C. This agent CRAd-CXCR4.RGD, as expected, improved both of the viral infectivity and tumor specificity as evaluated in an established lung tumor cell line and in primary tumor tissue from multiple patients. As an added benefit, the activity of the CXCR4 promoter was low in human liver as compared to three other promoters regularly used for targeting tumors. In addition, this agent has the potential of targeting multiple other tumor cell types. From these data, the CRAd-CXCR4.RGD appears to be a promising novel CRAd agent for lung cancer targeting with low host toxicity.

KW - Adenoviral vector

KW - CXCR4 gene

KW - Transcriptional targeting

KW - Tumor-specific promoter

UR - http://www.scopus.com/inward/record.url?scp=33846220985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846220985&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.10.012

DO - 10.1016/j.lungcan.2006.10.012

M3 - Article

C2 - 17113184

AN - SCOPUS:33846220985

VL - 55

SP - 145

EP - 156

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -